An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy
- PMID: 16452242
- DOI: 10.1158/0008-5472.CAN-05-2246
An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy
Abstract
Prior studies have shown that transfer of ovalbumin (OVA)-specific T helper type 1 (Th1) cells into mice bearing MHC class II+ OVA-expressing tumor cells (A20-OVA) causes complete tumor rejection. Here we show that, although Th1 cell therapy alone was not effective against MHC class II- OVA-expressing tumor cells (EG-7), treatment of mice bearing established EG-7 tumors by i.v. transfer of Th1 cells combined with i.t. injection of the model tumor antigen OVA induced complete tumor rejection. Transferred Th1 cells enhanced the migration of tumor-infiltrating antigen-presenting cells (APC) that had processed OVA into the draining lymph node (DLN). Although transferred Th1 cells were randomly distributed in DLN, distal LN, spleen, and tumor tissue, active proliferation of Th1 cells always initiated in DLN, where Th1 cells efficiently interacted with APC that presented OVA. In parallel, OVA-tetramer+ CTLs, showing EG-7-specific cytotoxicity, were highly induced in DLN and the local tumor site. The OVA-tetramer+ CTL functioned systemically because two bilateral tumor masses were both completely rejected on treatment of one tumor. Furthermore, either active proliferation of transferred Th1 cells or generation of tetramer+ CTL was not induced in MHC class II-deficient mice and LN-deficient Aly/Aly mice. These results indicate that DLN is an indispensable organ for initiating active APC/Th1 cell interactions, which is critical for inducing complete eradication of tumor mass by tumor-specific CTL.
Similar articles
-
Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.Int Immunol. 2007 Feb;19(2):151-61. doi: 10.1093/intimm/dxl132. Epub 2006 Dec 22. Int Immunol. 2007. PMID: 17189593
-
An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.Int Immunol. 2006 Mar;18(3):425-34. doi: 10.1093/intimm/dxh381. Epub 2006 Jan 13. Int Immunol. 2006. PMID: 16415100
-
Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.Cancer Lett. 2008 Feb 18;260(1-2):137-45. doi: 10.1016/j.canlet.2007.10.038. Cancer Lett. 2008. PMID: 18077084
-
T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.Crit Rev Immunol. 2001;21(1-3):215-48. Crit Rev Immunol. 2001. PMID: 11642606 Review.
-
Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.Cancer Treat Rev. 2004 May;30(3):281-90. doi: 10.1016/j.ctrv.2003.08.002. Cancer Treat Rev. 2004. PMID: 15059651 Review.
Cited by
-
Immune Effect of Co-Culture of Dendritic Cells and Cytokine-Induced Killer Cells on Prostate Cancer Cells.Cell Biochem Biophys. 2025 Jun;83(2):1593-1604. doi: 10.1007/s12013-024-01569-2. Epub 2024 Oct 25. Cell Biochem Biophys. 2025. PMID: 39448420
-
A Novel Inflammatory-Related Gene Signature Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma.Front Genet. 2022 Jan 5;12:798131. doi: 10.3389/fgene.2021.798131. eCollection 2021. Front Genet. 2022. PMID: 35069695 Free PMC article.
-
Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade.Ther Adv Med Oncol. 2022 May 6;14:17588359221096877. doi: 10.1177/17588359221096877. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35547094 Free PMC article.
-
Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation.Mol Ther. 2009 Jul;17(7):1274-81. doi: 10.1038/mt.2009.100. Epub 2009 May 5. Mol Ther. 2009. PMID: 19417739 Free PMC article.
-
TGF-β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up-regulation of IL-17RB.EMBO Mol Med. 2017 Dec;9(12):1660-1680. doi: 10.15252/emmm.201606914. EMBO Mol Med. 2017. PMID: 28993429 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials